https://www.europesays.com/unitedstates/112861/ [Pell Bio-Med Technology FY2026 Q3 Earnings Call] Pell Bio-Med to Restructure as Holding Company; Flagship CTL-001 Targets Taiwan’s First Regenerative Medicine Drug License in 2027, Small-Peptide Drug PL-021 to Enter U.S. via Right to Try in 2028 #AIBusiness #ArtificialIntelligence #CDE #CTL001 #CTL49 #Kymriah #LinChengLung #Peitai #PellBioMedTechnology #PL021 #PwC #RightToTry #SuperIntelligence #TCMC #technology #Technology&AIBusiness #TFDA #TRMAT #UPS #Yescarta
#ctl001 — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #ctl001, aggregated by home.social.